The Impact of Physical (In)Activity on Sleep Quality

Not Applicable

Completed

• Conditions: Sleep
• Interventions: Behavioral: Reduced Physical Activity

• Registration Number: NCT03514953
• Lead Sponsor: Virginia Commonwealth University

Brief Summary

The proposed research will examine the role of physical activity (PA) on altering sleep quality (SQ) while systematically examining novel mechanisms that may drive changes in SQ. Specifically, the study will examine how a 2 week reduction in PA alters sleep quality in young, healthy individuals. Additionally, during this reduction in PA, the study will examine changes in inflammation, oxidative stress, and sympathetic activity to identify potential mechanisms for alterations in sleep quality.

Detailed Description

Sleep, which makes up approximately one third of an individual's life, plays a vital role in normal bodily functioning by regulating metabolic and endocrine function. Disturbed sleep, defined as any alteration to normal sleep patterns, is highly prevalent, affecting 35% and 41% of the general population in the United States and has been linked to poor cardiovascular health, diabetes, obesity, dyslipidemia, and hypertension. Young adults are a population at high risk for disturbed sleep-related health outcomes due to negative lifestyle behaviors such as alcohol consumption, drug use, study patterns, and excessive screen time that remain with advancing age. Due to the importance of improving or maintaining health outcomes through adequate sleep quality (SQ), the proposed research will examine the role of physical activity (PA) on altering SQ while systematically examining novel mechanisms that may drive changes in SQ. Specifically, this study will examine how alterations (increases and decreases) in PA impact SQ and how these alterations modify inflammation, oxidative stress, and sympathetic stimulation in young adults.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2018-04-20
• Study First Submitted: 2018-04-20
• Study First Submitted QC: 2018-04-20
• Study First Posted: 2018-05-03
• Primary Completion: 2019-09-30
• Study Completion: 2019-09-30
• Status Verified: 2020-02
• Last Update Submitted: 2020-02-07
• Last Update Posted: 2020-02-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 33

Inclusion Criteria

• Healthy individuals with average weekly step count greater than 7500
• Low risk of cardiovascular, pulmonary, and metabolic disease

Read More

Exclusion Criteria

• Individuals with cardiovascular, pulmonary, and metabolic disease
• Individuals taking medications that may affect cardiovascular, pulmonary, and metabolic function
• Diet differs substantially from typical diet, significant calorie restriction, or vitamin/mineral deficiencies
• Pregnant women
• Prisoners

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Reduced Physical Activity	Reduced Physical Activity	Participants will reduce their physical activity level by \>5000 steps per day for two weeks.

Primary Outcome Measures

Name	Time	Method
Change in sleep quality (phase 1)	Day 7 to Day 21	Evaluation of sleep efficiency (the ratio of total sleep time to the total time recorded in which the subject was not asleep (i.e. brief awakenings))
Change in sleep quality (phase 2)	Day 21 to Day 28	Evaluation of sleep efficiency (the ratio of total sleep time to the total time recorded in which the subject was not asleep (i.e. brief awakenings))

Secondary Outcome Measures

Name	Time	Method
Level of Tumor Necrosis Factor Alpha in blood	Measured on Day 7, Day 14, Day 21, Day 28	Measurement of inflammation with greater levels indicating more inflammation
Level of Interleukin-6 in blood	Measured on Day 7, Day 14, Day 21, Day 28	Measurement of inflammation with greater levels indicating more inflammation
Level of Interleukin-1 in blood	Measured on Day 7, Day 14, Day 21, Day 28	Measurement of inflammation with greater levels indicating more inflammation
Level of Norepinephrine in blood	Measured on Day 7, Day 14, Day 21, Day 28	Measurement of catecholamine production with greater levels indicating more production
Level of Epinephrine in blood	Measured on Day 7, Day 14, Day 21, Day 28	Measurement of catecholamine production with greater levels indicating more production
Level of Lipid peroxidation in blood	Measured on Day 7, Day 14, Day 21, Day 28	Measurement of oxidative stress with greater levels indicating more oxidative stress
Protein oxidation in blood	Measured on Day 7, Day 14, Day 21, Day 28	Measurement of oxidative stress with greater levels indicating more oxidative stress
Change in Lower Limb Vascular Function	Measured on Day 7, Day 14, Day 21, Day 28	Measurement of popliteal artery dilation after 5 minutes of lower limb occlusion
Change in Upper Limb Vascular Function	Measured on Day 7, Day 14, Day 21, Day 28	Measurement of brachial artery dilation after 5 minutes of lower limb occlusion
Change in Leg Vascular Function	Measured on Day 7, Day 14, Day 21, Day 28	Measurement of leg blood flow during 1 minute of passive leg movement

Trial Locations

Locations (1)

Virginia Commonwealth University; 🇺🇸 Richmond, Virginia, United States